-
公开(公告)号：EP2243829B1
公开(公告)日：2014-08-20
申请号：EP09700904.7
申请日：2009-01-09
申请人： Astellas Pharma Inc.
发明人： UEHARA, Kenji , HIGUCHI, Hirofumi , NAKASHIMA, Toshihiro , ISHIKAWA, Daisuke , YAMAMOTO, Nobuchika , FUJITA, Hirotada , SAKAI, Fumihiko
IPC分类号： A61K39/395 , A61P29/00 , C07K16/28 , C07K16/46
CPC分类号： C07K16/2839 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
-
公开(公告)号：EP2025749B1
公开(公告)日：2012-04-11
申请号：EP07815053.9
申请日：2007-05-30
发明人： YAMAMOTO, Nobuchika , SAKAI, Fumihiko , HIGUCHI, Hirofumi , TORIKAI, Masaharu , NAKASHIMA, Toshihiro
IPC分类号： C07K16/24 , C12N15/09 , A61K39/395 , A61P19/02 , A61P29/00 , A61P37/06 , C07K16/18 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/56
摘要： It is intended to provide a humanized anti-human osteopontin antibody which is superior to conventional anti-human osteopontin antibodies in terms of activities (an antigen-binding activity, a leukocyte migration inhibitory activity and the like) and/or stability (resistance to heat, hypoxic conditions or denaturants, and the like).
-
公开(公告)号：EP2025749B8
公开(公告)日：2012-05-23
申请号：EP07815053.9
申请日：2007-05-30
发明人： YAMAMOTO, Nobuchika , SAKAI, Fumihiko , HIGUCHI, Hirofumi , TORIKAI, Masaharu , NAKASHIMA, Toshihiro
IPC分类号： C07K16/24 , C12N15/09 , A61K39/395 , A61P19/02 , A61P29/00 , A61P37/06 , C07K16/18 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/56
摘要： It is intended to provide a humanized anti-human osteopontin antibody which is superior to conventional anti-human osteopontin antibodies in terms of activities (an antigen-binding activity, a leukocyte migration inhibitory activity and the like) and/or stability (resistance to heat, hypoxic conditions or denaturants, and the like).
-
公开(公告)号：EP2239323A1
公开(公告)日：2010-10-13
申请号：EP09700866.8
申请日：2009-01-09
发明人： UEHARA, Kenji , HIGUCHI, Hirofumi , NAKASHIMA, Toshihiro , ISHIKAWA, Daisuke , YAMAMOTO, Nobuchika , FUJITA, Hirotada , SAKAI, Fumihiko
IPC分类号： C12N15/00 , A61K39/395 , A61P29/00 , C07K16/28 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12P21/08
CPC分类号： C07K16/2839 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides a humanized anti-human α9 integrin antibody having improved activity and/or property as compared to donor mouse anti-human α9 integrin antibody, namely, a humanized anti-human α9 integrin antibody comprising a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 1 or the amino acid sequence shown by SEQ ID NO: 1 wherein one or several amino acids are substituted, deleted, inserted and/or added and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO: 61 or the amino acid sequence shown by SEQ ID NO: 61 wherein one or several amino acids are substituted, deleted, inserted and/or added, as well as a means for preventing or treating various diseases involving human α9 integrin in their pathogenesis, which uses the antibody.
摘要翻译： 本发明提供与供体小鼠抗人±9整联蛋白抗体相比具有改善的活性和/或性质的人源化抗人±9整联蛋白抗体，即包含重链变量的人源化抗人±9整联蛋白抗体 由SEQ ID NO：1所示的氨基酸序列或SEQ ID NO：1所示的氨基酸序列组成的区域，其中一个或几个氨基酸被取代，缺失，插入和/或加入，以及轻链可变区 的SEQ ID NO：61所示的氨基酸序列或SEQ ID NO：61所示的氨基酸序列，其中一个或几个氨基酸被取代，缺失，插入和/或添加，以及用于预防或治疗的手段 各种疾病涉及人类±9整联蛋白在其发病机理中，其使用抗体。
-
公开(公告)号：EP2025749A1
公开(公告)日：2009-02-18
申请号：EP07815053.9
申请日：2007-05-30
发明人： YAMAMOTO, Nobuchika , SAKAI, Fumihiko , HIGUCHI, Hirofumi , TORIKAI, Masaharu , NAKASHIMA, Toshihiro
IPC分类号： C12N15/09 , A61K39/395 , A61P19/02 , A61P29/00 , A61P37/06 , C07K16/18 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12P21/08 , G01N33/53
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/24 , C07K2317/56
摘要： The present invention provides a humanized anti-human osteopontin antibody having better activities (antigen binding activity, leukocyte migration inhibitory activity and the like) and/or stability (resistance to heat, low-pH conditions, denaturants and the like) than those of conventional anti-human osteopontin antibodies.
摘要翻译： 本发明提供具有比常规的更好的活性（抗原结合活性，白细胞迁移抑制活性等）和/或稳定性（耐热，低pH条件，变性剂等）的人源化抗人骨桥蛋白抗体 抗人骨桥蛋白抗体。
-
6.发明公开
公开(公告)号：EP2243829A1
公开(公告)日：2010-10-27
申请号：EP09700904.7
申请日：2009-01-09
发明人： UEHARA, Kenji , HIGUCHI, Hirofumi , NAKASHIMA, Toshihiro , ISHIKAWA, Daisuke , YAMAMOTO, Nobuchika , FUJITA, Hirotada , SAKAI, Fumihiko
IPC分类号： C12N15/00 , A61K39/395 , A61P29/00 , C07K16/28 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12P21/08
CPC分类号： C07K16/2839 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The present invention provides a humanized anti-human α9 integrin antibody having improved activity and/or property as compared to a donor mouse anti-human α9 integrin antibody, namely, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:11 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:13 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:17, a humanized anti-human α9 integrin antibody containing a heavy-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:15 and a light-chain variable region consisting of the amino acid sequence shown by SEQ ID NO:9, and a means for the prophylaxis or treatment of various diseases involving human α9 integrin in the pathogenesis, which uses the antibody.
摘要翻译： 本发明提供与供体小鼠抗人±9整联蛋白抗体相比具有改善的活性和/或性质的人源化抗人±9整联蛋白抗体，即含有重链的人源化抗人±9整联蛋白抗体 由SEQ ID NO：11所示的氨基酸序列组成的可变区和由SEQ ID NO：17所示的氨基酸序列组成的轻链可变区，包含重链的人源化抗人±9整联蛋白抗体 由SEQ ID NO：13所示的氨基酸序列组成的可变区和由SEQ ID NO：17所示的氨基酸序列组成的轻链可变区，包含重链的人源化抗人±9整联蛋白抗体 由SEQ ID NO：15所示的氨基酸序列组成的可变区和由SEQ ID NO：9所示的氨基酸序列组成的轻链可变区，以及预防或治疗涉及人类± 9整数 rin在发病机制中，其使用抗体。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.009 秒)
